MedTrace Logo

A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

NCT01263899 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-04-20

No results posted yet for this study

Summary

This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).

Conditions

Interventions

DRUG

SB1518

SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.

Sponsors & Collaborators

  • S*BIO

    lead INDUSTRY

Principal Investigators

  • Anas Younes, MD · MD Anderson Cancer Center at University of Texas, Houston

  • Jonathan Friedberg, MD · University of Rochester James P. Wilmot Cancer Center

  • Peter Martin, MD · Weill Medical College of Cornell University

  • Julie Vose, MD · University of Nebraska

  • Richard Klasa, MD · British Columbia Cancer Center - Vancouver Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01263899 on ClinicalTrials.gov